Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man

References

• Aellig W. H., Nüesch E. Comparative pharmacokinetic investigations with tritium-labelled ergot alkaloids after oral and intravenous administration in man. International Journal of Clinical Pharmacology 1977; 15: 106–112
   Google Scholar
• Arndts D., Foster H. J. New aspects in the metabolism of alinidine in man. European Journal of Drug Metabolism and Pharmacokinetics 1981; 6: 313–315
   Google Scholar
• Brambilla E., Di Salle E., Briatico G., Mantegani S., Temperilli A. Synthesis and nidation inhibitory activity of a new class of ergoline derivatives. European Journal of Medicinal Chemistry 1989; 24: 421–426
   Web of Science ®Google Scholar
• Cocchiara G., Strolin Benedetti M. Excretion balance and urinary metabolic pattern of [3H]cabergoline in man. Drug Metabolism and Drug Interactions 1992; 10: 199–211
   Google Scholar
• Di Salle E., Ornati G., Briatico G. FCE 21336, a new ergoline derivative with a potent and long-acting lowering effect on prolactin secretion in rats. Journal of Endocrinological Investigation 1982; 5: 45
   Google Scholar
• Di Salle E., Ornati G., Giudici D., Briatico G. Prolactin lowering effect of a new ergoline derivative, FCE 21336, in the rat: a comparison with bromocriptine. Acta Endocrinologica 1983; 103: 265
   Google Scholar
• Drenth B. F. H., Jagersma T., Overzet F., Ghijsen R. T., De Zeeuw R. A. Assessment of radioactivity measurements on HPLC effluents. Drug Metabolite Isolation and Determination, E. Reid, J. P. Leppard. Plenum, New York 1983; 75–80
   Google Scholar
• Eckert H., Kiechel J. R., Rosenthaler J., Schmidt R., Schreier E. Biopharmaceutical aspects. Ergot Alkaloids and Related Compounds, B. Berde, H. O. Schild. Springer-Verlag, Berlin 1978; 719–803
   Google Scholar
• Ferrari C, Barbieri C., Caldara R., Mucci M., Codecasa F., Paracchi A., Romano C., Boghen M., Dubini A. Long-lasting prolactin lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. Journal of Clinical Endocrinology and Metabolism 1986; 63: 941–945
   PubMed Web of Science ®Google Scholar
• Fischer I. U., Von Unruh G. E., Dengler H. J. The metabolism of eugenol in man. Xenobiotica 1990; 20: 209–222
   PubMed Web of Science ®Google Scholar
• Franceschi M., Bassi S., Calloni E., Camerlingo M., Frattola L., Giusti M. C., Jori M. C., Mamoli A., Piolti R., Canal N. Evaluation of cabergoline, a new ergoline derivative, for the treatment of Parkinson's disease. Journal of Neurology 1988; 235: 53–54, suppl. S
   Google Scholar
• Goodnow R., Konno K., Niwa M., Kollimopoulos T., Bukownik R., Lehares D., Nakanishi K. Synthesis of glutamate receptor antagonist philanthotoxin-433 (PhTX-433) and its analogs. Tetrahedron 1990; 46: 3267–3286
   Google Scholar
• Gorrod J. W. Biological Oxidation of Nitrogen. Elsevier Biomedical Press), (North Holland and New York 1978
   Google Scholar
• Hümpel M., Toda T., Oshino N., Pommerenke G. The pharmacokinetics of lisuride hydrogen maleate in rat, rabbit and Rhesus monkey. European Journal of Drug Metabolism and Pharmacokinetics 1981; 6: 207–219
   PubMedGoogle Scholar
• Iwamoto K., Klaassen C. D. First-pass effect of nalorphine in rats. Journal of Pharmacology and Experimental Therapeutics 1977; 203: 365–376
   PubMed Web of Science ®Google Scholar
• Johnson P., Rising P. A. Techniques for assessment of biliary excretion and enterohepatic circulation in the rat. Xenobiotica 1978; 8: 27–36
   PubMed Web of Science ®Google Scholar
• Jori M. C., Dubini A. Cabergoline in Parkinson's disease: a confirmation of the role of a long-lasting dopaminergic stimulation in motor fluctuations. Movement Disorders 1990; 5: 62, Suppl. 1
   Google Scholar
• Krause W., Hümpel M. Pharmacokinetics of the dopamine partial agonist, terguride, in the rat and rhesus monkey. European Journal of Drug Metabolism and Pharmacokinetics 1988a; 13: 85–194
   Google Scholar
• Krause W., Hümpel M. Pharmacokinetics of proterguride in rat and Cynomolgus monkey. Xenobiotica 1988b; 18: 41–48
   PubMed Web of Science ®Google Scholar
• Krause W., Kühne G., Seifert W. Pharmacokinetics of 3H-terguride in elderly volunteers. Arzneimittel Forschung—Drug research 1991; 41(11)373–377
   Google Scholar
• Mantegani S., Brambilla E., Ermoli A., Fontana E., Angiuli P., Vicario G. P. Syntheses of tritium and carbon-14 labelled N-(3-dimethylaminopropyl)-N-(ethylaminocarbonyl)-6 -(2-propenyl)ergoline-8β-carboxamide (cabergoline), a potent long lasting prolactin lowering agent. Journal of Labelled Compounds and Radiopharmaceuticals 1991; 24: 519–533
   Google Scholar
• Maurer G., Frick W. Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. European Journal of Clinical Pharmacology 1984; 26: 463–470
   PubMed Web of Science ®Google Scholar
• Maurer G., Schreier E., Delaborde S., Nufer R., Shukla A. P. Fate and disposition of bromocriptine in animals and man. II. Absorption, elimination and metabolism. European Journal of Drug Metabolism and Pharmacokinetics 1983; 8: 51–62
   PubMed Web of Science ®Google Scholar
• Mc Omie J. F. K. Protective Groups in Organic Chemistry. Plenum), (New York 1973
   Google Scholar
• Ninomiya I., Kiguchi T. Ergot alkaloids. The Alkaloids, A. Brossi. Academic, San Diego 1990; 1–156
   Google Scholar
• Parli C. J., Schmidt B., Shaar C. J. Metabolism of lergotrile to 13-hydroxy lergotrile, a potent inhibitor of prolactin release. in vitro. Biochemical Pharmacology 1978; 27: 1405–1408
   Google Scholar
• Perlemutter P. Conjugate Addition Reaction in Organic Synthesis. Pergamon), (Oxford 1992
   Google Scholar
• Pontiroli A. E., Viberti G. C., Mangili R., Cammelli L., Orlandini L., Pozza G., Dubini A. Long-lasting prolactin lowering effect of FCE 21336 in man. Journal of Endocrinological Investigation 1985; 8: 103
   Google Scholar
• Rubin A., Lemberger L., Dhahir P. Physiologic disposition of pergolide. Clinical Pharmacology and Therapeutics 1981; 30: 258–265
   Google Scholar
• Rubin A., Lemberger L., Dhahir P., Warrick P., Crabtree R. E., Obermeyer B. D., Wolen R. L., Rowe H. Physiologic disposition of lergotrile. Clinical Pharmacology and Therapeutic 1978; 23: 272–280
   Google Scholar
• Siddik Z. H., Barnes R. D., Dring L. G., Smith R. L., Williams R. T. The fate of lysergic acid di [14C]ethylamide ([14C]LSD) in the rat. Biochemical Society Transactions 1975; 3: 290–292
   PubMed Web of Science ®Google Scholar
• Strolin Benedetti M., Dostert P., Barone D., Efthymiopoulos C., Peretti G., Roncucci R. In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine. European Journal of Pharmacology 1990; 187: 399–408
   Google Scholar
• Tateoka Y., Kimura T., Watanabe K., Yamamoto I., Hume A. S., Ho I. K. N,N'-diallylpentobarbital (DAPB) metabolites and their effects on pentorbarbital-induced sleep and hepatic drug-metabolizing enzymes. Xenobiotica 1989; 19: 1355–1368
   Web of Science ®Google Scholar
• Vaughan J. R. Acylalkylcarbonate as acylating agents for the synthesis of peptides. Journal of American Chemical Society 1951; 73: 3547
   Web of Science ®Google Scholar